Fred Hutchinson Cancer Center

Fred Hutch Cancer Center provides the latest cancer treatment options and is known for breakthroughs impacting both cancer and infectious diseases worldwide. Fred Hutch is an independent organization that also serves as the cancer program for UW Medicine. To learn more, visit: https://www.fredhutch.org/en.html

For the latest Fred Hutch oncology educational events click here.

 

Leukemia
05:20

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-Cell Malignancies

FEATURING Mazyar Shadman
  • 1 view
  • December 18, 2024
05:58

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Ibrutinib or Acalabrutinib in CLL - Impact of Dose Reduction on Therapy Duration

FEATURING Mazyar Shadman
  • 16 views
  • December 17, 2024
14:31

Fred Hutchinson Cancer Center

Current Guideline-Informed Treatment of CLL

FEATURING Chaitra Ujjani
  • 47 views
  • December 13, 2024
16:28

Fred Hutchinson Cancer Center

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and Beyond

FEATURING Ryan Cassaday
  • 451 views
  • April 29, 2024
  • 4
07:25

Fred Hutchinson Cancer Center

FDA Approval of Liso-Cel in R/R CLL: What You Need to Know

FEATURING Mazyar Shadman
  • 149 views
  • March 26, 2024
20:28

Insights from 2023 ASH Annual Meeting

Clinically-Relevant Updates in ALL in Adults

FEATURING Ryan Cassaday
  • 261 views
  • February 20, 2024
  • 1
06:56

Insights from 2023 ASH Annual Meeting

Efficacy of Ibrutinib Arms Across ALPINE and ELEVATE-RR Trials in R/R CLL: A Matching-Adjusted Indirect Comparison

FEATURING Mazyar Shadman
  • 824 views
  • December 19, 2023
  • 1
07:04

Insights from 2023 ASH Annual Meeting

Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patients With CLL/SLL

FEATURING Mazyar Shadman
  • 408 views
  • December 19, 2023
  • 4
12:17

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Achieving Best Response Is Desirable Prior to Allogeneic Hematopoietic Cell Transplantation in AML

FEATURING Roland B. Walter
  • 23 views
  • October 19, 2023
18:39

Fred Hutchinson Cancer Center

MRD Positivity in ALL: Next Steps in Clinical Approach

FEATURING Ryan Cassaday
  • 267 views
  • May 5, 2023
  • 1
06:53

Fred Hutchinson Cancer Center

Surveying Safety and Efficacy Data in R/R CLL: ALPINE and ELEVATE-RR Trials

FEATURING Mazyar Shadman
  • 522 views
  • March 23, 2023
  • 2
18:26

Fred Hutchinson Cancer Center

4-Year MURANO Study Follow-up: PFS and OS Benefits Are Sustained With Time-Limited Venetoclax-Rituximab Compared With Bendamustine-Rituximab in R/R CLL

FEATURING Mazyar Shadman
  • 460 views
  • January 20, 2020
  • 3
23:37

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH 2018 AML: Deciding Between Standard vs Investigational Therapies & Problems in Evaluating New Therapies, MRD and HCT

FEATURING Elihu H. Estey
  • 571 views
  • March 19, 2019
05:54

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - MRD in AML - What is the Benefit / Risk Ratio Related to HCT?

FEATURING Elihu H. Estey
  • 197 views
  • March 19, 2019
14:49

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH 2018 AML Challenges in Evaluating New Therapies: Understanding the Recent FDA Approvals

FEATURING Elihu H. Estey
  • 181 views
  • March 19, 2019
06:26

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - AML - Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies

FEATURING Elihu H. Estey
  • 42 views
  • March 19, 2019